BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

InNexus Inc. Announces A Scientific Discovery And Expansion Of Its SuperAntibody Intellectual Property


10/19/2005 5:10:46 PM

VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov. 14, 2003--InNexus Biotechnology, Inc. (the "Company") announced today the scientific discovery that its SuperAntibodies can form an association (one antibody with the other, referred to as "dimerization") and that this appears to be related to their high potency in disease treatment. This discovery has enabled InNexus to file an additional patent that protects more uses of SuperAntibody Technology ("SAT") and will ultimately allow InNexus to work with more corporate partners. This discovery, recently published by InNexus's collaborators, Immpheron, Inc. of Lexington, Kentucky, has shown that monoclonal antibodies can be conjugated through carbohydrate linkage to a peptide capable of conferring a dimerizing ability to antibodies. The specific studies utilized antibodies to the B-cell receptor, present on normal and malignant B-cells, and demonstrated that such modified antibodies were superior at inducing apoptosis ("cell suicide") and in growth inhibition as well as binding better than an unmodified, native antibody - all key properties of therapeutically active antibodies.

The peer-reviewed publication referenced herein has been published and is posted on InNexus's website (www.innexusbiotech.com). The citation is: "Enhanced Tumor Targeting and Apoptosis Using Non-Covalent Antibody Homodimers," Y Zhao and H Kohler. J. Immunotherapy 25(5) :396-404, 2002.

Dr. Charles Morgan, President of InNexus commented, "This key scientific discovery is important for allowing InNexus to file for additional patent protection that enhances the intellectual property base for SAT. It will also enable SAT to appeal to more potential corporate partners and allow InNexus to develop antibodies for the treatment of additional forms of cancer and other life-threatening diseases."

InNexus has recently entered into an agreement with Corixa Corp (NASDAQ:CRXA - News) to use SAT with up to four of their antibodies currently in development.

About InNexus

InNexus is developing the next generation of therapeutic, monoclonal antibodies using its SuperAntibody Technology Platform. InNexus intends to apply this technology to improve the potency of existing antibody products while opening new markets and disease applications with other forms of SuperAntibodies. InNexus intends to develop the technology through partnerships with biotechnology and pharmaceutical companies while pursuing development of its own products for unmet medical needs. To learn more about InNexus please visit the Company's website: www.innexusbiotech.com.

On behalf of the Board of Directors of InNexus Biotechnology Inc. A. CHARLES MORGAN President

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.

The TSX Venture Exchange has neither approved or disapproved of this news release.

Contact:

InNexus Biotechnology Inc. Investor Relations: Toll Free: 888-271-0788 or 866-990-8382 investor@innexusbiotech.com or

InNexus Biotechnology Inc. Toll Free: A. Charles Morgan, 877-990-8382 Fax: 425-696-0068 business@innexusbiotech.com www.innexusbiotech.com

Source: InNexus Biotechnology Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES